3.238.250.73
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-

Alagille Syndrome

FDA label expansion makes maralixibat available for infants 3 months and older with ALGS

The U.S. Food and Drug Administration approved a reduction in age from 1 year to 3 months for maralixibat (Livmarli; Mirum) oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS), according to a press release. The label expansion was based on data from the RISE...

Read More
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-